NATR NATURES SUNSHINE PRODUCTS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 275053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.2%
TTM net income YoY-2.9%
TTM EPS YoY1.2%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR22.0%
Margins
Gross margin73.1%
Operating margin5.3%
Net margin3.1%
FCF margin2.2%
EBITDA margin8.1%
Returns
ROE8.8%
ROA5.5%
ROIC (approx.)21.5%
Asset turnover1.80x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.56x
Interest coverage176.76x
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $480.14M | $454.36M | $445.32M | $421.91M | $444.08M |
| Cost of revenue | $132.42M | $129.68M | $124.19M | $122.15M | $115.47M |
| Gross profit | $347.72M | $324.69M | $321.13M | $299.76M | $328.62M |
| R&D expense | $1.90M | $1.70M | $1.60M | $1.50M | $1.40M |
| SG&A expense | $178.39M | $164.00M | $167.06M | $153.12M | $154.10M |
| Operating income | $24.74M | $20.09M | $18.75M | $16.26M | $34.67M |
| Interest expense | $98,000 | $146,000 | $69,000 | $249,000 | $250,000 |
| Pretax income | $29.81M | $18.43M | $20.20M | $15.21M | $31.82M |
| Income tax | $9.36M | $10.53M | $3.79M | $14.66M | $1.61M |
| Net income | $19.52M | $7.70M | $15.08M | -$390,000 | $28.85M |
| EBITDA | $38.59M | $34.31M | $30.57M | $27.28M | $45.83M |
| EPS (basic) | 1.08 | 0.41 | 0.79 | -0.02 | 1.45 |
| EPS (diluted) | 1.06 | 0.40 | 0.77 | -0.02 | 1.42 |
| Dividends declared per share | — | — | — | 0.00 | 1.00 |
| Weighted avg. shares (diluted) | 18.47M | 19.09M | 19.47M | 19.33M | 20.33M |
| Balance sheet | |||||
| Cash & equivalents | $93.89M | $84.70M | $82.37M | $60.03M | $86.18M |
| Receivables | $8.60M | $9.48M | $8.83M | $14.11M | $8.87M |
| Inventory | $68.31M | $59.44M | $66.89M | $67.95M | $60.85M |
| Current assets | $178.84M | $160.58M | $165.82M | $149.51M | $164.67M |
| PP&E, net | $32.91M | $39.59M | $45.00M | $46.16M | $50.86M |
| Total assets | $261.15M | $240.85M | $249.77M | $229.78M | $258.87M |
| Current liabilities | $78.54M | $65.69M | $76.75M | $65.58M | $76.67M |
| Short-term debt | — | — | $0 | $1.17M | $1.24M |
| Long-term debt | — | — | $0 | $0 | $1.17M |
| Total debt | — | — | $0 | $1.17M | $2.42M |
| Total liabilities | $99.59M | $79.86M | $90.23M | $82.73M | $97.47M |
| Shareholders' equity | $161.55M | $155.31M | $154.06M | $142.91M | $158.20M |
| Net debt | — | — | -$82.37M | -$58.86M | -$83.77M |
| Shares outstanding | 17.51M | 18.48M | 18.88M | 19.09M | 19.72M |
| Cash flow statement | |||||
| Operating cash flow | $35.32M | $25.30M | $41.23M | $710,000 | $34.61M |
| Capital expenditure | $6.48M | $10.97M | $10.48M | $7.63M | $6.67M |
| Free cash flow | $28.84M | $14.33M | $30.75M | -$6.92M | $27.94M |
| Investing cash flow | -$6.48M | -$10.97M | -$10.48M | -$7.63M | -$6.61M |
| Financing cash flow | -$23.77M | -$9.90M | -$7.96M | -$16.25M | -$31.72M |
| Depreciation & amortization | $13.84M | $14.22M | $11.82M | $11.03M | $11.16M |
| Stock-based compensation | $5.78M | $4.79M | $4.89M | $2.90M | $3.73M |
| Dividends paid | — | — | — | $0 | $19.86M |
| Share buybacks | $16.31M | $8.86M | $6.40M | $13.57M | $7.42M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.